NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Down 0.2 %

NASDAQ NURO opened at $4.03 on Friday. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $4.70. The firm’s fifty day simple moving average is $4.03 and its 200-day simple moving average is $3.88. The company has a market capitalization of $8.18 million, a PE ratio of -0.73 and a beta of 2.29.

NeuroMetrix (NASDAQ:NURO) last issued its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share for the quarter. The firm had revenue of $0.77 million during the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.